Welcome to our dedicated page for Ardelyx SEC filings (Ticker: ARDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ardelyx, Inc. filings document a commercial-stage biopharmaceutical company with U.S. product revenue from IBSRELA and XPHOZAH and development activity centered on tenapanor and NHE3 inhibition. Form 8-K reports cover quarterly operating results, preliminary product sales, cash and investment updates, Regulation FD presentation materials, and other material-event disclosures tied to the company’s commercial and clinical programs.
Ardelyx proxy materials describe annual meeting proposals, director elections, say-on-pay matters, auditor ratification, executive compensation, board structure, and stockholder voting mechanics. Additional current reports record officer appointments, executive transitions, transition and separation agreements, compensatory arrangements, governance matters, and disclosure controls relevant to the company’s public-company reporting obligations.
Ardelyx Director Muna Bhanji reported two equity compensation grants on June 18, 2025:
- 41,551 Restricted Stock Units (RSUs) awarded at $0, bringing total direct common stock ownership to 137,353 shares
- 54,059 Stock Options granted with a strike price of $3.61, exercisable until June 18, 2035
The equity awards were issued under Ardelyx's Non-Employee Director Compensation Program. The stock options vest monthly at 1/12th of shares, with accelerated vesting at the next annual stockholder meeting if unvested portions remain. The RSUs convert 1:1 to common stock upon vesting. This Form 4 filing indicates standard board compensation rather than open market transactions, reflecting ongoing director compensation arrangements.
Ardelyx Director William C. Bertrand Jr. reported multiple equity transactions on June 18, 2025, significantly increasing his beneficial ownership position:
- Acquired 19,390 shares of common stock at $0 through the Non-Employee Director Compensation Program, choosing stock instead of cash compensation
- Received 41,551 Restricted Stock Units (RSUs) under the same program, convertible 1:1 into common shares upon vesting
- Granted stock options to purchase 54,059 shares at $3.61 per share, expiring June 18, 2035. Options vest monthly at 1/12th rate with potential acceleration at next annual stockholder meeting
Following these transactions, Bertrand directly owns 290,707 shares of common stock and 54,059 stock options. These grants reflect standard non-employee director compensation rather than open market transactions.
Ardelyx Director David M. Mott has increased his position in the company through a significant stock purchase on June 16, 2025. Mott acquired 200,000 shares of common stock at a weighted average price of $3.6294 per share, with individual trade prices ranging from $3.57 to $3.70.
Following this transaction, Mott's total beneficial ownership stands at 2,896,871 shares held directly. Of this total, 87,566 shares are held for the benefit of entities associated with New Enterprise Associates, for which Mott disclaims beneficial ownership except for his pecuniary interest.
This insider purchase by a director signals potential confidence in the company's prospects. The transaction was reported via Form 4 filing, executed through multiple trades, and was filed within the required reporting period. The filing was completed through an attorney-in-fact on June 19, 2025.
Ardelyx held its 2025 Annual Meeting of Stockholders on June 18, 2025, where shareholders voted on four key proposals. 187,162,927 shares out of 239,255,212 outstanding shares were represented at the meeting.
Key outcomes include:
- Board Elections: Class II directors David Mott and Michael Raab were elected to serve until 2028, with Raab receiving stronger shareholder support (101.2M vs 93M votes)
- Say-on-Pay: Approved with strong support (131.3M votes in favor)
- Auditor Ratification: Ernst & Young LLP confirmed as independent auditor with overwhelming approval (182.5M votes in favor)
- Equity Plan Amendment: The amendment to the Amended and Restated 2014 Equity Incentive Award Plan passed with moderate support (85M votes for vs 57.4M against)
The meeting demonstrated generally positive shareholder sentiment, though the Equity Plan Amendment faced notable opposition with approximately 40% of voting shares against the proposal.